A Wave of Humira Biosimilars Hit the US Market
July 4, 2023
Several new biosimilars to AbbVie’s Humira (adalimumab) have just hit the US market in the past week, bringing a new wave of competition for the expensive top-selling therapeutic of all time. The copycats come from companies like Organon, Samsung Bioepsis, Sandoz, and Boehringer Ingelheim. Hadlima, a product of Samsung and Organon, will retail for 85% less than brand name Humira.
According to Nicole Raleigh, “According to Drugs.com, the price of two subcutaneous kits of Humira can cost between $7,299 to $14,588, depending on dosage, and the biosimilars launched this first week in July aim to offer a much better deal. Indeed, a recent study by the Leonard D Shaeffer Center for Health Policy & Economics at the University of Southern California found that biosimilars promote such healthy competition and price reduction.”
To read more, click here.
(Source: Pharmaphorum, July 4th, 2023)
